

0560

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:

Friedhoff, et al.

Serial No. 09/704,554

Filed: November 3, 2000

For: Method of Treating Amyloid β Precursor Disorders



Art Unit: Not Assigned

Examiner: Not Assigned

Atty. Docket: 0200-0004

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified application, Applicants herewith respectfully request the following amendments:

IN THE CLAIMS:

In claim 9, line 24, please change "micromolar" to --nanomolar--.

In claim 10, line 3, please change "micromolar" to --nanomolar--.

In claim 11, line 6, please change "micromolar" to --nanomolar--.

In claim 12, line 9, please change "micromolar" to --nanomolar--.

In claim 13, line 12, please change "micromolar" to --nanomolar--.

Support may be found in the specification generally. Specifically, on page 37, lines 7-12, the applicants show that 0.05 μ M LA was an effective concentration and is equal to 50 nM LA. Additionally, on page 10, lines 22-23, and Figure 7, the applicants show effective plasma concentrations in clinical human studies in about 3 to about 4 mg/mL which is roughly converted to nM by multiplying by 1,000 and


dividing by the molecular weight of lovastatin acid which is about 422. Therefore, the effective concentration is about 7 nM to about 9.5 nM. Thus, the specification provides support for nM concentration ranges from about 7 nM to about 50 nM. Accordingly, no new matter has been added and entry of this amendment is respectfully requested.

It is respectfully requested that the Examiner enter these amendments prior to examining the application on its merits.

Respectfully submitted,

SHANKS & HERBERT

By:


Suzannah K. Sundby
Reg. No. 43,172

Date: 5 December 2000

TransPotomac Plaza
1033 N. Fairfax Street
Suite 306
Alexandria, VA 22314
(703) 683-3600